SmaBio Labs
Private Company
Funding information not available
Overview
SmaBio Labs is a private, revenue-generating CDMO founded in 2018, offering comprehensive development and manufacturing services for biologics and antibodies. The company leverages a skilled team with over 100 years of combined experience and a proven track record of 200+ projects to deliver faster turnaround times and expert guidance. Its business model is centered on providing seamless, US-based services to biotechnology and pharmaceutical partners, with a strong focus on Quality by Design and Process Analytical Technology approaches.
Technology Platform
Integrated CDMO services utilizing Quality by Design (QbD) and Process Analytical Technology (PAT) approaches for end-to-end biologics and antibody development and manufacturing.
Opportunities
Risk Factors
Competitive Landscape
SmaBio Labs competes in the crowded biologics CDMO space against giants like Lonza and Catalent, as well as many specialized firms. Its differentiation is based on claimed faster turnaround times, direct expert access, and a US-based operational focus for IP-sensitive clients, rather than competing on global scale alone.